3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
285
Lymphoma
201
Lymphoma, Large B-Cell, Diffuse
167
Sarcoma
141
Precursor Cell Lymphoblastic Leukemia-Lymphoma
109
Hodgkin Disease
85
Lymphoma, Non-Hodgkin
78
Burkitt Lymphoma
67
Lymphoma, Follicular
61
Leukemia
58
Ovarian Neoplasms
50
Neoplasms
50
Triple Negative Breast Neoplasms
49
Lymphoma, Mantle-Cell
48
Multiple Myeloma
47
Neuroblastoma
44
Carcinoma, Hepatocellular
44
Neoplasm Metastasis
41
Lymphoma, B-Cell
33
Lymphoma, Large-Cell, Anaplastic
31
Lymphoma, T-Cell, Peripheral
27
Recurrence
26
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
25
Osteosarcoma
25
Liposarcoma
25
Leiomyosarcoma
25
Urinary Bladder Neoplasms
23
Lymphoma, Large-Cell, Immunoblastic
23
Liver Neoplasms
22
Endometrial Neoplasms
21
Interventions
Pemetrexed
9
Nivolumab
8
Cisplatin
8
Carboplatin
8
pembrolizumab
7
130-nm albumin-bound paclitaxel
7
Gemcitabine
6
padeliporfin
5
durvalumab
5
Paclitaxel
5
Bevacizumab
5
palbociclib
4
napabucasin
4
atezolizumab
4
Irinotecan
4
Fulvestrant
4
Fluorouracil
4
Cyclophosphamide
4
ribociclib
3
osimertinib
3
cobimetinib
3
alectinib
3
abemaciclib
3
Trastuzumab
3
Sunitinib
3
Radiosurgery
3
Drug Therapy
3
Docetaxel
3
Cetuximab
3
Anastrozole
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Neoplasms by Site
×
Doxorubicin
×
Clear all
NCT01204801
2015-09-24
Medifocus301
Medifocus, Inc.
Phase 3
Unknown
238 enrolled